AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AVECHO BIOTECHNOLOGY LTD

0.020

+0.00211.11%

Volume:554.90K

Turnover:11.00K

Market Cap:77.27M

PE:-20

High:0.020

Open:0.019

Low:0.019

Close:0.018

52wk High:0.027

52wk Low:0.005

Shares:3.86B

Float Shares:1.90B

Volume Ratio:0.14

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.001

EPS(LYR):-0.001

ROE:-268.21%

ROA:-25.82%

PB:40.52

PE(LYR):-14.29

Loading ...

Overview Company News Filings

Avecho Biotechnology Ltd-Avecho Enters Final Stage of Phase Iii Insomnia Trial

THOMSON REUTERS

We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

Simply Wall St.

Avecho Biotechnology Ltd-Avecho Strengthens Bd Capability with Senior Appointment

THOMSON REUTERS

Avecho Biotechnology Says Japanese Patent Granted for CBD Capsule

Avecho Biotechnology Ltd-Japanese Patent Granted for Cbd Capsule

THOMSON REUTERS

Avecho to Continue With Full Enrollment in Insomnia Trial After Positive Data Monitoring Board Recommendation; Shares Hit 5.5-Year High

MT Newswires Live

BRIEF-Avecho Biotechnology Seeks Trading Halt

Avecho Biotechnology - Seeks Trading Halt Pending Outcome of Phase Iii Cbd Tpm Capsule Trial Analysis

THOMSON REUTERS

Avecho Biotechnology Ltd-Resignation of Non-Executive Director

THOMSON REUTERS

Avecho Biotechnology Receives AU$1.98 Million Under Australian R&D Tax Incentive Scheme

MT Newswires Live

Avecho Biotechnology Completes Treatment Phase for Interim Analysis of Third-Phase Insomnia Trial

MT Newswires Live

Avecho Biotechnology Ltd-Change of Company Secretary

THOMSON REUTERS

2025 Special Purpose Annual Report Progress 2023-2 Trust-POH

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/AVE.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AVE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AVE.AU\",,,,,undefined,":{"symbol":"AVE.AU","market":"AU","secType":"STK","nameCN":"AVECHO BIOTECHNOLOGY LTD","latestPrice":0.02,"timestamp":1790921520000,"preClose":0.018,"halted":0,"volume":554901,"delay":0,"changeRate":0.11111111111111122,"nameEN":"AVECHO BIOTECHNOLOGY LTD","floatShares":1896395886,"shares":3863725873,"eps":-0.001,"marketStatus":"Closed","change":0.002,"latestTime":"10-02 16:12:00 AEST","open":0.019,"high":0.02,"low":0.019,"amount":10998,"amplitude":0.055556,"askPrice":0.02,"askSize":220831,"bidPrice":0.019,"bidSize":1474743,"shortable":3,"etf":0,"ttmEps":-0.001,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791154800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.018,"openAndCloseTimeList":[[1790899200000,1790920800000]],"volumeRatio":0.137583,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"AVE.AU","preClose":0.019,"auctionPrice":0.018,"auctionVolume":1495,"auction":3,"marketStatus":"盘后竞价","timestamp":1790834994337}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AVE.AU\",,,,,undefined,":{"symbol":"AVE.AU","floatShares":1896395886,"roa":"-25.82%","roe":"-268.21%","lyrEps":-0.0014,"volumeRatio":0.137583,"shares":3863725873,"dividePrice":0,"high":0.02,"amplitude":0.055556,"preClose":0.018,"low":0.019,"week52Low":0.005,"pbRate":"40.52","psRate":"104.81","week52High":0.027,"institutionHeld":0,"latestPrice":0.02,"committee":0.739521,"eps":-0.001,"divideRate":0,"volume":554901,"delay":0,"ttmEps":-0.001,"open":0.019,"prevYearClose":0.009,"prevWeekClose":0.02,"prevMonthClose":0.019,"prevQuarterClose":0.019,"fiveDayClose":0.02,"twentyDayClose":0.021,"sixtyDayClose":0.022},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVE.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVE.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVE.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663401790","title":"Avecho Biotechnology Ltd-Avecho Enters Final Stage of Phase Iii Insomnia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2663401790","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663401790?lang=en_us&edition=fundamental","pubTime":"2026-08-31 07:15","pubTimestamp":1788131755,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260830:nTUE3B3KLG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662725231","title":"We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely","url":"https://stock-news.laohu8.com/highlight/detail?id=2662725231","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662725231?lang=en_us&edition=fundamental","pubTime":"2026-08-27 06:20","pubTimestamp":1787782841,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, Avecho...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ave/avecho-biotechnology-shares/news/were-hopeful-that-avecho-biotechnology-asxave-will-use-its-c-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ave/avecho-biotechnology-shares/news/were-hopeful-that-avecho-biotechnology-asxave-will-use-its-c-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","AVE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661490192","title":"Avecho Biotechnology Ltd-Avecho Strengthens Bd Capability with Senior Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2661490192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661490192?lang=en_us&edition=fundamental","pubTime":"2026-08-24 07:54","pubTimestamp":1787529266,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260823:nTUE5QWC6P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656346629","title":"Avecho Biotechnology Says Japanese Patent Granted for CBD Capsule","url":"https://stock-news.laohu8.com/highlight/detail?id=2656346629","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656346629?lang=en_us&edition=fundamental","pubTime":"2026-08-03 07:49","pubTimestamp":1785714569,"startTime":"0","endTime":"0","summary":"BRIEF-Avecho Biotechnology Says Japanese Patent Granted For CBD CapsuleAug 3 (Reuters)-Avecho Biotechnology LtdAVE.AX:JAPANESE PATENT GRANTED FOR CBD CAPSULEFurther company coverage:AVE.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260802:nTUE7DBFNR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","AVE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656648346","title":"Avecho Biotechnology Ltd-Japanese Patent Granted for Cbd Capsule","url":"https://stock-news.laohu8.com/highlight/detail?id=2656648346","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656648346?lang=en_us&edition=fundamental","pubTime":"2026-08-03 07:48","pubTimestamp":1785714504,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260802:nTUE7DBFNR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645863328","title":"Avecho to Continue With Full Enrollment in Insomnia Trial After Positive Data Monitoring Board Recommendation; Shares Hit 5.5-Year High","url":"https://stock-news.laohu8.com/highlight/detail?id=2645863328","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645863328?lang=en_us&edition=fundamental","pubTime":"2026-06-24 09:20","pubTimestamp":1782264025,"startTime":"0","endTime":"0","summary":"Avecho Biotechnology  said an independent data monitoring board recommended that the company's phase 3 clinical trial evaluating TPM-enhanced cannabidiol capsule for insomnia continue to the full planned enrolment of 519 participants, according to a Wednesday filing with the Australian bourse.The data monitoring board issued the recommendation following an interim analysis that showed no serious adverse events across 244 initial participants.\"The interim analysis represents a major value-inflection point for the program, reducing clinical development risk and providing a defined pathway toward completion of the pivotal study,\" the company said.Avecho added that it has already identified additional clinical sites to speed up the recruitment of the second patient cohort.The company's shares gained 33% in recent Wednesday activity and earlier hit their highest since December 2020.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","AVE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645019464","title":"BRIEF-Avecho Biotechnology Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2645019464","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645019464?lang=en_us&edition=fundamental","pubTime":"2026-06-22 06:31","pubTimestamp":1782081110,"startTime":"0","endTime":"0","summary":"BRIEF-Avecho Biotechnology Seeks Trading Halt June 22 (Reuters) - Avecho Biotechnology Ltd AVE.AX:SEEKS TRADING HALT PENDING OUTCOME OF PHASE III CBD TPM CAPSULE TRIAL ANALYSISFurther company coverage: AVE.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260621:nFWN42S063:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645019495","title":"Avecho Biotechnology - Seeks Trading Halt Pending Outcome of Phase Iii Cbd Tpm Capsule Trial Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2645019495","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645019495?lang=en_us&edition=fundamental","pubTime":"2026-06-22 06:31","pubTimestamp":1782081093,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260621:nFWN42S063:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AVE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638079587","title":"Avecho Biotechnology Ltd-Resignation of Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2638079587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638079587?lang=en_us&edition=fundamental","pubTime":"2026-05-25 14:00","pubTimestamp":1779688854,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260525:nTUE4V3BDQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AVE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637936999","title":"Avecho Biotechnology Receives AU$1.98 Million Under Australian R&D Tax Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2637936999","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637936999?lang=en_us&edition=fundamental","pubTime":"2026-05-22 09:31","pubTimestamp":1779413483,"startTime":"0","endTime":"0","summary":"Avecho Biotechnology  said it has received AU$1.98 million for the year ended Dec. 31, 2025, under the Australian Government's research and development tax incentive scheme, according to a Friday Australian bourse filing.The company said AU$1.62 million of the funds will be used to repay Endpoint Capital for advances on the company's R&D tax credit paid over the past year, with the remainder to support operations and advance its commercialization strategy.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","OZR.AU","OZF.AU","IOZ.AU","BBOZ.AU","E200.AU","GIVE.AU","ZYAU.AU","STW.AU","IISV.AU","AVE.AU","SLF.AU","VAP.AU","IMLC.AU","EIGA.AU","XJO.AU","DACE.AU","GEAR.AU","IIGF.AU","QRE.AU","XAO.AU","VAS.AU","BEAR.AU","QFN.AU","XKO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637808265","title":"Avecho Biotechnology Completes Treatment Phase for Interim Analysis of Third-Phase Insomnia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2637808265","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637808265?lang=en_us&edition=fundamental","pubTime":"2026-05-21 10:21","pubTimestamp":1779330079,"startTime":"0","endTime":"0","summary":"Avecho Biotechnology  completed the treatment phase for the last patient required for the planned interim analysis of its pivotal third-phase insomnia trial evaluating its tocopheryl phosphate mixture-enhanced cannabidiol capsule, according to a Thursday filing with the Australian bourse.The analysis is expected to provide the first indication of the product's efficacy profile, determine the number of participants needed for the final study, and support ongoing licensing discussions, the filing said.Results are expected in late June, per the filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","AVE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632943736","title":"Avecho Biotechnology Ltd-Change of Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2632943736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632943736?lang=en_us&edition=fundamental","pubTime":"2026-05-01 12:39","pubTimestamp":1777610385,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nTUE2ZWW6D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AVE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627553416","title":"2025 Special Purpose Annual Report Progress 2023-2 Trust-POH","url":"https://stock-news.laohu8.com/highlight/detail?id=2627553416","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627553416?lang=en_us&edition=fundamental","pubTime":"2026-04-14 16:05","pubTimestamp":1776153959,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260414:nASX9CtHKj","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nASX9N1BHM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","AVE.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}]}}